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ABSTRACT
Despite considerable efforts to prevent and treat cardiovascular disease (CVD), it has become 
the leading cause of death worldwide. Cardiac mitochondria are crucial cell organelles 
responsible for creating energy-rich ATP and mitochondrial dysfunction is the root cause for 
developing heart failure. Therefore, maintenance of mitochondrial quality control (MQC) 
is an essential process for cardiovascular homeostasis and cardiac health. In this review, we 
describe the major mechanisms of MQC system, such as mitochondrial unfolded protein 
response and mitophagy. Moreover, we describe the results of MQC failure in cardiac 
mitochondria. Furthermore, we discuss the prospects of 2 drug candidates, urolithin A and 
spermidine, for restoring mitochondrial homeostasis to treat CVD.
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INTRODUCTION
The mammalian heart is highly oxidative, consuming high levels of oxygen to generate 
adenosine triphosphate (ATP) for myocyte contraction and relaxation.1) Mitochondria 
are highly dynamic cell organelles that take part in a wide-range of functions. In cardiac 
myocytes, mitochondria are crucial for heart function through oxidative ATP generation. In 
addition to energy production, mitochondria play a role in fatty acid synthesis, amino acid 
production, heme synthesis, iron-sulfur cluster biogenesis, and act as a signaling hub for 
innate immunity and cell death.2) Mitochondrial dysfunction leads to energetic dysfunction, 
oxidative stress, calcium dysregulation, and cardiomyocyte death.3) Therefore, mitochondrial 
dysfunction is currently being considered as a potential therapeutic target.
To achieve mitochondrial homeostasis and maintain a healthy mitochondrial status, cardiac 
myocytes have quality control mechanisms known as mitochondrial quality control (MQC) 
systems.4) For the maintenance of mitochondrial protein homeostasis, mitochondria contain 




Chang-Myung Oh , MD, PhD1,*, Dongryeol Ryu , PhD2,3,4,*,  
Sungsoo Cho , MD, PhD5, and Yangsoo Jang , MD, PhD6
1 Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, 
Gwangju, Korea
2Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea
3Biomedical institute for Convergence at SKKU (BICS), Sungkyunkwan University (SKKU), Suwon, Korea
4Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
5 Division of Cardiovascular Medicine, Department of Internal Medicine, Dankook University College of 
Medicine, Dankook University Hospital, Cheonan, Korea
6 Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea
Mitochondrial Quality Control in 
the Heart: New Drug Targets for 
Cardiovascular Disease
Received: Dec 26, 2019
Revised: Jan 27, 2020
Accepted: Feb 18, 2020
Correspondence to
Yangsoo Jang, MD, PhD
Division of Cardiology, Department of 
Internal Medicine, Severance Hospital, Yonsei 
University College of Medicine, 50-1, Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea.
E-mail: JANGYS1212@yuhs.ac
*Chang-Myung Oh and Dongryeol Ryu 
contributed equally to this work.
Copyright © 2020. The Korean Society of 
Cardiology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted noncommercial 
use, distribution, and reproduction in any 












This research was supported by the Basic 
Science Research Program through the 
National Research Foundation of Korea (NRF), 
which is funded by the Ministry of Education 
(2016R1A6A3A04010466 to C.M.O.) and 
(2017R1D1A1B03032708 to D.R.).
Conflict of Interest
The authors have no financial conflicts of 
interest.
Author Contributions
Conceptualization: Oh CM, Ryu D, Cho S, 
Jang Y; Funding acquisition: Oh CM, Ryu D; 
Methodology: Oh CM, Ryu D; Resources: Oh 
CM; Visualization: Oh CM; Writing - original 
draft: Oh CM, Ryu D, Cho S, Jang Y; Writing - 
review & editing: Jang Y.
diverse chaperons and proteases that facilitate communication with other organelles, termed 
mitochondria-cytosol-nucleus crosstalk.5) If damages in the mitochondria are not rescued, 
the disrupted mitochondria are engulfed by an autophagosome for lysosome degradation.6)
Recent studies revealed the significant role of mitochondrial dysfunction in heart disease 
and the emergence of mitochondrial function restoration as a novel therapeutic target.7-9) In 
this review, we discuss the MQC systems and their role in cardiac protection and heart failure 
development. We then describe novel drug candidates (urolithin A and spermidine) for the 
treatment of cardiovascular disease (CVD) by maintaining mitochondrial homeostasis and 
restoring mitochondrial function.
MITOCHONDRIAL QUALITY CONTROL SYSTEMS
Mitochondrial proteostasis
The mitochondria are a central hub of cellular metabolism and signaling. Therefore, 
keeping the proteomic integrity in the mitochondria is crucial for cell survival.10) To protect 
the heart under stressful conditions, protein homeostasis is maintained through several 
mechanisms or “proteostasis” within the mitochondria. Mitochondrial proteostasis includes 
mitochondrial-localized chaperons and proteases, degradation of bulk mitochondrial 
organelles, mitochondrial-nuclear communications, and transcellular signaling (e.g., 
mitokine signals) (Figure 1).11-13) To protect the mitochondrial proteome against reactive 
oxygen species (ROS) damage and misfolded protein toxicity, mitochondria have localized 
protective machines such as chaperones, antioxidant enzymes, and proteases within 
mitochondria. The key chaperones include mitochondrial Hsp70 (mtHsp70), mtHSP90, 
and the large chaperonin Hsp60/10 complex, which fold nascent polypeptides or repair 
misfolded proteins.14-16) Superoxide dismutase enzymes such as SOD2 in the mitochondrial 
matrix and SOD1 in the intermembrane space (IMS) protect the mitochondria from ROS 
damage.17) Several proteases in the mitochondrial matrix (e.g., LonP1 and ClpP) and within 
the IMS (e.g., m-AAA and i-AAA) degrade damaged mitochondrial proteins.18) In addition, 
mitochondrial dynamic processes such as mitochondrial fusion and fission also play a role in 
maintaining healthy mitochondria. Mitochondrial fusion dilutes the effects of small amounts 
of damage19) while mitochondrial fission separates damaged mitochondria from healthy 
mitochondria. Segregated mitochondria are subsequently degraded by mitophagy.20)
Only 13 proteins are encoded within the mtDNA, while 1,000–1,500 resident mitochondrial 
proteins are encoded by nuclear DNA.21) This implies that most mitochondrial proteins 
should be correctly folded within the cytoplasm and imported into the mitochondria.22) 
Therefore, vast communication between the mitochondria and other cellular compartments 
is expected. The mitochondrial unfolded protein response (UPRmt) and mitophagy are two 
major mechanisms for maintaining mitochondrial proteostasis, which include intracellular 
communication, in the context of the cell.22)
Unfolded mitochondrial protein response
Poor quality mitochondria increase cellular oxidative stress and degenerative apoptosis 
signals leading to cell death.23) Disrupted mitochondrial proteostasis and dysfunction 
initiates a retrograde signaling pathway from the mitochondria to the nucleus. This 
retrograde signaling, known as UPRmt, initiates a transcriptional program to relieve 
mitochondrial stress.24) The UPRmt is a coordinated response mediated by mitochondrial-
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nuclear communications, triggered by mtDNA depletion or protein misfolding in the 
mitochondrial matrix.25) Although this pathway was discovered in mammalian cells, parts 
of its regulation mechanism have been discovered in worms. In Caenorhabditis elegans, 
mitochondrial proteotoxicity reduces the mitochondrial import efficiency of a stress activated 
transcription factor, activating transcription factor associated with stress (ATFS)-1, which 
is the potential transcription factor mammalian ortholog of activating transcription factor 
(ATF) 4, ATF5, and C/EBP homologous protein.22) Under physiologic condition, ATFS-1 goes 
into the mitochondria and is degraded by a Lon protease.25) As a result of mitochondrial 
perturbation, mitochondrial import is compromised and allows ATFS-1 to be trafficked to 
the nucleus. Once there, it induces hundreds of genes associated with proteases, antioxidant 
enzymes, and genes involved in mitochondrial dynamics, protein import, and cellular 
metabolism.22)
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Figure 1. Mitochondrial quality control system. Under normal condition, ATFS-1 and PINK1 proteins goes into mitochondria and are degraded. After mitochondrial 
stress, disrupted mitochondrial integrity and function induces mitochondrial stress responses for restoring mitochondrial and cellular homeostasis. ATFS-1 
traffics to the nucleus and activates transcriptional responses to recover mitochondrial function. Damaged mitochondria are marked by PINK1 and removed by 
mitophagy pathway. 
ATFS = activating transcription factor associated with stress; FGF = fibroblast growth factor; GDF = growth differentiation factor; PINK1 = PTEN-induced kinase 1; 
Ub = ubiquitin; ROS = reactive oxygen species.
Interestingly, there are significant differences in the mammalian UPRmt signaling cascade 
compared to C. elegans. For example, C. elegans mitochondrial ClpP protease has a central role 
generating peptides and acting as a retrograde messenger by proteolyzing misfolded proteins. 
However, genetical ClpP depletion in the hearts of mice did not affect UPRmt signaling.26)
In the mammalian mitochondria, ATF5 is a proposed mediator of UPRmt.27) In previous 
studies, pharmacological induction of UPRmt was found to play a role in protecting the 
heart of wild-type (WT) mice after ischemia-reperfusion (I/R) injury but was not involved 
in protecting ATF5 knockout mice hearts. Further RNA sequencing results revealed that 
UPRmt induced ATF5-dependent pathway contributes to cardioprotection.28) Another possible 
additional main regulator of UPRmt in mammals is ATF4. By treating HeLa cells with 4 
therapeutic drugs (doxycycline, actinonin, FCCP, MitoBloCK-6) altering mitochondrial 
proteostasis and performing multi-omics analyses, Pedro M. et al. reported that ATF4 
coordinates mitochondrial stress response.29) ATF4 is essential to maintain cell proliferation 
and protect the cell against mitochondrial stress; however, it is not involved in mtDNA 
metabolism.29)
Mitophagy
Mitophagy is a critical MQC mechanism in cardiac myocytes. Impaired mitophagy leads to 
accumulation of aberrant mitochondria, loss of myocytes, and contractile dysfunction.30) 
Mitophagy is defined as mitochondrial degradation through the macroautophagy pathway.23) 
This removal process is necessary for maintenance of the MQC systems. Selective removal of 
dysfunctional mitochondria is extremely complex and requires mitochondrial and cytosolic 
proteins to perform highly coordinated functions to maintain healthy mitochondria; this 
is essential for cell metabolism and survival.23) An important pathway in mitophagy is the 
PTEN-induced kinase 1 (PINK1)/Parkin pathway. Under physiologic conditions, the PINK1 
is imported into the mitochondrial matrix to be degraded by LonP1. However, in membrane 
deficient mitochondria, PINK1 accumulates on the outer mitochondrial membrane.31) 
This leads to the recruitment of E3 ubiquitin ligase and Parkin from the cytosol and 
transference to the mitochondrial membrane (PINK1-dependent Parkin translocation), 
where Parkin initiates ubiquitination of multiple outer membrane proteins.32) Mitophagy 
also takes place through a Parkin-independent pathway. Some mitophagy receptor proteins 
on the mitochondrial outer membrane (e.g., BNIP3, FUNDC1, Bcl2-L-13, AMBRA1, and 
cardiolipin) bind to LC3 in a Parkin-independent manner.33) Under hypoxic conditions, 
BNIP3 promotes mitophagy and protects cells from oxidative damage.34) FUNDC1 interacts 
with LC3 to activate Parkin-independent mitophagy in response to hypoxia and hypoxic 
mitophagy in platelets protecting the heart from IR injury in the FUNDC1-dependent 
mitophagy.35) Bcl2-L-13 induces mitochondrial fragmentation and mitophagy in HEK293 
cells.36) Cardiolipin, a phospholipid stabilizing OXPHOS complex, is synthesized in the 
mitochondrial inner membrane and translocated to the outer membrane, where it initiates 
mitophagy to protect the cell from cell apoptosis under mitochondrial stress conditions.11)
MITOCHONDRIAL QUALITY CONTROL AND HEART 
DISEASE
UPRmt and heart disease
Nicotinamide riboside (NR) is well-known for boosting UPRmt by augmenting NAD+ pools.37) 
Smyrnias et al.3) reported that UPRmt boosting by NR improves heart function in the mice 
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model of pressure overload-induced heart failure. Mice were treated with NR or a control 
vehicle for 3 days prior to subjecting them to transverse aortic constriction (TAC) surgery. At 
1 week post TAC surgery, NR treated mice showed improved left ventricle (LV) function in 
the echocardiogram and reduced cardiomyocyte death in histologic analysis.3) Research from 
Xu et al.38) also reported a UPRmt boosting by choline-attenuated cardiac dysfunction in the 
rat model pressure overload-induced heart failure through the SIRT1-AMPK pathway. Aortic 
stenosis (AS) is the clinical model of chronic pressure overload.39) Myocardial tissue from 
AS patients showed that UPRmt mRNA marker levels increased in AS patients compared to 
control subjects. In the subgroup analysis of AS patients, UPRmt markers levels had a negative 
correlation with cardiomyocyte tissue death, fibrosis, and cardiac damage markers.5)
UPRmt activation also showed cardioprotective effects against heart I/R injury models. Wang 
et al.40) examined the role of UPRmt in perfused heart IR injury models with ATF5 knock out 
(KO) mouse. When the UPRmt was activated using oligomycin and doxycycline treatment, 
WT mice hearts exhibited significant improvement in post-IR functional recovery and infarct 
size. However, this protective effect was absent in ATF5 KO mice hearts. Nicotinamide 
mononucleotide (NMN), a NAD+ boosting agent like NR, also exhibited cardioprotective 
effects in the IR injury model. Nadtochiy et al.41) reported that NMN pretreatment showed 
significant protection against IR injury (post-IR functional recovery: NMN, 42±7% vs. 
vehicle, 11±3%; infarct size: NMN, 34±4% vs. vehicle, 66±4%).
Mitophagy and heart disease
Mitophagy plays a key role in the removal of damaged mitochondria in response to 
several stresses such as hypoxia and cytosolic Ca2+ overload.42) Previous studies report 
that mitophagy has an essential role in the development of heart failure. Protein levels 
of PINK1 in LV heart samples from end stage HF patients were decreased compared with 
normal controls.43) Previous research indicates that PINK1 KO mice developed cardiac 
hypertrophy at 2 months of age,43) and loss of PINK1 increased infarct size after I/R injury.44) 
Parkin KO mice accumulated abnormal mitochondria with increasing age.30) Although 
young Parkin KO mice had normal cardiac function, these mice were more sensitive to 
myocardial infarction (MI) than WT mice; moreover, they possessed a reduced mitophagy, 
the accumulated swollen, and dysfunctional mitochondria within the heart of the MI rat 
model.45) Mitophagy also showed a protective role against pressure overload induced heart 
failure by TAC.46)
Diabetic cardiomyopathy (DCM) is a cardiac phenotype of diabetic patients. DCM is 
defined as the existence of abnormal myocardial structure and performance in the 
absence of additional cardiac risk factors.47) Diabetes-derived mitochondrial dysfunction 
has an essential role in DCM development.48) The DCM-affected mitochondria portray 
a dysregulation of Ca2+ handling, alternations in energy metabolism, and an increased 
oxidative stress.49) Mitophagy activation has shown protective effects against high fat diet 
(HFD)-induced DCM in mice studies. A study done by Tong et al.50) in Parkin KO mice 
reported that mitophagy was upregulated and there were severe cardiac hypertrophy and 
diastolic dysfunctions after mice consumption of HFD. Enhancing PINK1/Parkin-mediated 
mitophagy using melatonin has been found to decrease DCM-derived dysfunctional 
mitochondria in mice.51) Recent studies using animal models further reveal mitophagy role 
in heart disease (Table 1).30)43-45)52-56)
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NOVEL CANDIDATES FOR MITOCHONDRIAL QUALITY 
CONTROL IN THE HEART
Urolithin A
Numerous studies have reported the beneficial effects of phytochemicals in metabolic 
disease, such as metabolic syndrome and CVD.57)58) Urolithin A is the well-known gut 
microbiota-generated small metabolite from pomegranate fruits. Natural compounds known 
as ellagitannins from pomegranate juice are hydrolyzed in the gut to release ellagic acid. 
Colonic microflora converts ellagic acid to urolithins and enter the systemic circulation.59) 
Ryu et al.60) reported that urolithin A improves mitochondrial proteostasis by inducing 
mitophagy. Urolithin A supplementation also extended lifespan in C. elegans and improved 
skeletal muscle function in mice.56)
The pomegranate fruit has shown beneficial effects in CVD. Pomegranate juice improves 
stress-induced myocardial ischemia in patients who have coronary heart disease61) and 
inhibits atherosclerosis development.62) These findings suggest potential benefits of urolithin 
A in cardiac myocytes which many studies have revealed throughout the years. In rodents, 
urolithin metabolites accumulate in the myocardium after urolithin A admiration.63) Urolithin 
A activates mitophagy signal in cardiac myocytes and suppresses cardiac fibrosis,64) reduces 
cardiac tissue inflammation, and improves cardiac function in the streptozotocin-induced 
DCM rat model.63) Recent human clinical trials revealed that urolithin A also improves 
mitochondrial function in human skeletal muscle.65) These results suggest that urolithin A 
may improve mitochondrial and heart muscle function in CVD human patients.
Spermidine
Spermidine is a natural polyamine abundant in certain foods, such as rice bran, soybeans, 
aged cheese, mushrooms, and broccoli.66) This polyamine has shown beneficial effects in 
many diseases by improving mitochondrial function. Spermidine stimulates Ca2+ uptake 
in isolated mitochondria from mice liver, heart, and brain.67) In mice neuroblastoma cells, 
spermidine treatment protects mitochondrial damage, stabilizes mitochondrial genome 
and membrane potential, and reduces apoptosis due to D-galactose (gal)-induced stress.68) 
A combination of spermidine and exercise rescues skeletal muscle atrophy in D-gal-induced 
aging rats.69)
In addition, spermidine portrayed cardiovascular protective effects in previous studies. 
Spermidine feeding led to a 10% increase in the median lifespan of C57BL/6J mice and 
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Table 1. Genetically modified mice and their cardiac phenotypes
Model Mitophagy Phenotypes Ref
Parkin KO Decreased Increased sensitivity to MI and doxorubicin exposure, accumulation of 
dysfunctional mitochondria, and oxidative damage with age, reduced life span
45)52)53)
Parkin TG Increased Increased life span, preserved cardiac function with aging 52)54)
PINK1 KO NA Mitochondrial dysfunction, cardiomyopathy, increased sensitivity to I/R 43)44)
BNIP3 KO NA Decreased apoptosis and cardiac remodeling in response to I/R 55)
BNIP3 TG NA Increased sensitivity to MI, increased apoptosis 55)
NIX KO NA Decreased cardiac remodeling and preserved cardiac function in response to 
pressure overload
56)
NIX TG NA Ventricular dilation, reduced cardiac function 56)
Reproduced from “Mitophagy and heart failure.” By Shires and Gustafsson, Journal of Molecular Medicine 
2015;93:253-62.30)
I/R = ischemia-reperfusion; KO = knock out; MI = myocardial infarction; NA = not assessed; I/R = ischemia-reperfusion; 
TG = transgenic.
delayed heart failure progression in Dahl rats.70) In similar studies, spermidine reduced 
inflammation, induced autophagy and mitophagy, increased mitochondrial respiration in 
the heart, and improved heart function in aged mice.71) In a human cohort study, spermidine 
levels declined with aging,72) and spermidine intake showed inversed association with heart 
failure, acute coronary artery disease, stroke, and death due to vascular disease.73) Therefore, 
spermidine supplementation shows promise for CVD prevention and treatment.
CONCLUSIONS
Mitochondria have numerous roles essential for energy metabolism, cell cycle control, cell 
development, immune response, and cell death. Scientists regard the mitochondria as a 
central platform in the execution of diverse cellular events74) and see vast potential in using 
mitochondrial dysfunction as a therapeutic target for human diseases such as CVD. Targeting 
of UPRmt, mitophagy, or both, as a novel therapeutic strategy with optimistic potential in 
improving human heart disease. Future research focusing on the machinery regulating 
mitochondrial proteostasis under various stress conditions is needed to unveil the new 
molecular pathways of MQC.
Drugs targeting the mitochondria such as NR and spermidine have already shown good 
clinical activity and beneficial effects in age-related human disease.75)76) Urolithin A also 
showed beneficial effects in elderly skeletal muscle improvement.65) These clinical data 
provide good promise and excitement over novel therapeutic options against heart disease 
as discussed within this review. Further researches aimed at identifying new compounds 
enhancing mitochondrial proteostasis and long-term clinical studies are needed for the 
prevention of heart disease and the recovery of heart function in CVD patients.
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